Navigation Links
OxThera coordonne le projet Elimox du 7e PC - 2,19 millions EUR dédiés au développement d'un médicament pour traiter l'hyperoxalurie
Date:9/24/2013

STOCKHOLM, September 24, 2013 /PRNewswire/ --

OxThera AB a annoncé aujourd'hui être le coordinateur d'un nouveau projet européen, Elimox, planifié sur 2 ans et financé par le 7e PC à hauteur de 2,19 millions EUR. L'objectif principal de ce projet est le développement d'un médicament pharmaceutique bactérien innovant et unique, destiné au traitement d'une maladie héréditaire grave et invalidante : l'hyperoxalurie primaire.

« Nous sommes extrêmement heureux d'obtenir cette contribution au développement d'un traitement de l'hyperoxalurie primaire », a expliqué Elisabeth Lindner, coordonnatrice du projet Elimox et PDG d'OxThera. « Les résultats de recherche issus de ce projet permettront d'apporter des connaissances approfondies sur l'impact des traitements pharmaceutiques probiotiques et de leur rôle ultérieur en matière de santé et de maladie », a poursuivi Mme Lindner.

Le projet Elimox comprendra le développement de médicaments bactériens, l'élaboration de méthodes d'analyse et un développement clinique concernant l'hyperoxalurie primaire. Il a été démontré que la bactérie Oxalobacter formigenes favorise activement l'élimination entérique d'oxalate sur des sujets animaux (Hatch, 2011 et 2013). Les premières études cliniques exploratoires évaluant une formulation initiale des bactéries ont montré une baisse importante de l'excrétion urinaire d'oxalate chez les sujets atteints d'hyperoxalurie primaire (Hoppe, 2006).

À propos du projet Elimox

Le projet Elimox est financé dans le cadre du programme « 
'/>"/>

SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OxThera stärker patentportfölj för särläkemedel - Primär hyperoxaluri
2. OxThera stärkt sein Patentportfolio für primäre Hyperoxalurie, eine seltene Krankheit
3. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
4. Bausch + Lomb soumet une déclaration denregistrement pour un projet doffre publique initiale
5. New Vision Hope For Millions Undergoing Cataract Surgery
6. Producer Austin Chapman Reaches Millions with Inspiring Story on Hearing Loss; Launches Contest in Partnership with Phonak
7. Philips ermöglicht noch besseren Zugang zu Behandlungen für häufige Todesursache in den USA durch Bereitstellung seines einmillionsten AED
8. Info Graphic: Middle managers are frozen by information overload, costing companies millions
9. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
10. Millions Around the World to Have Access to Low-Cost HIV Test by 2013
11. Flexpoint Receives Purchase Order for Medical Device Used in Procedure Performed Millions of Times Annually
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... HAIKOU, China , April 22 /PRNewswire-Asia-FirstCall/ ... (OTC Bulletin Board: KURU), a,leading bio-pharmaceutical company in ... peptide-based drugs and small molecule drugs, today,announced the signing ... of preferred stock and warrants with Caduceus Asia ...
... CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and ... spotlighted in three publications during the month of April: Today,s Medical ... Transcript . , , ... the April 2010 print and online editions of Today,s ...
Cached Medicine Technology:Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 2Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 3Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 4CardioGenics to be Spotlighted in Three Publications During Month of April 2CardioGenics to be Spotlighted in Three Publications During Month of April 3CardioGenics to be Spotlighted in Three Publications During Month of April 4
(Date:12/19/2014)... December 20, 2014 The Medspa at ... injectable filler from respected cosmetic brand Juvéderm. Voluma XC ... with age. The Medspa at Hendrick is pleased to ... skin care technology to its clients. , Voluma is ... be FDA-approved to treat the mid-face and cheek area. ...
(Date:12/19/2014)... News) -- New research warns parents that buying an older car ... Nearly half of teen drivers killed in the United States between ... years old and often lacked important safety features that are available ... drivers killed in crashes were in cars at least six years ... 31 percent were in cars 11 to 15 years old, and ...
(Date:12/19/2014)... 2014 (HealthDay News) -- All children should have their ... preferably every year, eye experts say. The new ... panel of the U.S. National Center for Children,s Vision ... age group require screening for eye problems, particularly vision ... amblyopia ("lazy eye") and strabismus (a disorder of eye ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Injectable drug ... double the suicide attempt rate of other substance users, ... use is associated with the risk of suicide attempt ... the University of Montreal, said in a university news ... users. We wanted to know who among substance users ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The cost of ... well-being, a new study finds. Researchers examined data ... been diagnosed with colorectal or lung cancer. Of those ... cancer-free, and more than 100 had advanced cancer. ... to pay their medical bills, which was linked with ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2
... Feb. 18 As National Eating Disorders Awareness,Week approaches, ... and body image issues for millions of Americans, including ... public and healthcare professionals about males and eating,disorders is ... from,these disorders and very few professionals would even consider ...
... Safety Cautions of the Complications and Consequences of Growing and ... ... 18, 2009 -- Life-threatening kidney-failure is a strong and convincing ... a true threat to beauty and to health, cautions Physicians ...
... healthcare manufacturer introduces new product packaging and ,e-commerce feature to company ... ... Vernon, NY (PRWEB) February 18, 2009 -- The Geritrex Corporation, a ... now celebrating its 30th year in business. Founded by CEO ...
... withdrawal symptoms without side effects, early study shows , , ... used to treat nausea can prevent symptoms of withdrawal ... morphine and codeine, a new study shows. , The ... do so without some of the serious side effects ...
... conditions, report says , , WEDNESDAY, Feb. 18 (HealthDay News) -- ... the United States was born in a state that required ... by the end of 2008, all 50 states and the ... screening for at least 21 disorders, a new report finds. ...
... of Sciences will release a report, ... could improve the forensic sciences., ... United States: A Path Forward," ... forensic techniques--fingerprinting, firearms, ...
Cached Medicine News:Health News:Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009 2Health News:Inexpensive and Illegal Buttock - Boosting Injections Not Pretty 2Health News:Inexpensive and Illegal Buttock - Boosting Injections Not Pretty 3Health News:Inexpensive and Illegal Buttock - Boosting Injections Not Pretty 4Health News:Inexpensive and Illegal Buttock - Boosting Injections Not Pretty 5Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2Health News:Nausea Drug Shows Promise Against Opioid Addiction 2Health News:Newborn Screenings Now Required Across U.S. 2Health News:Newborn Screenings Now Required Across U.S. 3Health News:NAS Releasing Forensics Report: Expert Available 2
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
Medicine Products: